Bristol Myers Squibb (CELG-RI) Income towards Parent Company (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Income towards Parent Company of $2.7 billion for Q1 2026, up 8.81% year-over-year from $2.5 billion in Q1 2025, and up 146.69% quarter-over-quarter from $1.1 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Income towards Parent Company (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Income towards Parent Company data on file, last reported at $2.7 billion in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at $2.7 billion, up 8.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (up 197.81% YoY), and the FY2025 annual result was $7.1 billion, up 178.99% from the prior year.
- Income towards Parent Company rose to $2.7 billion in Q1 2026 per CELG-RI's latest filing, from $1.1 billion in the prior quarter.
- Over five years, Income towards Parent Company peaked at $2.7 billion in Q1 2026 and troughed at -$11.9 billion in Q1 2024.
- A 5-year average of $883.5 million and a median of $1.6 billion in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company sank 625.28% in 2024, then soared 1328.95% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at $2.0 billion in 2022, then fell by 15.7% to $1.7 billion in 2023, then plunged by 95.55% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
- Business Quant data shows CELG-RI's Income towards Parent Company at $2.7 billion in Q1 2026, $1.1 billion in Q4 2025, and $2.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 2.20 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 2.46 Bn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 1.16 Bn |
| Jun 30, 2024 | 1.63 Bn |
| Mar 31, 2024 | -11.91 Bn |
| Dec 31, 2023 | 1.71 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 2.08 Bn |
| Mar 31, 2023 | 2.27 Bn |
| Dec 31, 2022 | 2.03 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 1.28 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 1.48 Bn |
| Jun 30, 2021 | 995.00 Mn |